GlobeNewswire·Nov 12, 2026, 4:16 PM ET

Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results

VRCA

Verrica Pharmaceuticals reported record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, an 11.9% increase from the previous quarter and a 57.9% year-over-year rise, with total revenue reaching $6.9 million.
The company completed enrollment in the first of two pivotal Phase 3 trials for common warts, with topline data expected in Q1 2027, while the second trial (COVE-3) has over 50% enrollment completion and is projected to report data in mid-2027.
Verrica achieved pre-defined milestones to unlock the full $27.5 million non-dilutive growth capital under its credit facility, extending its cash runway through the data readouts for both common warts trials.
The company is exploring the development of its oncolytic peptide VP-315 for the treatment of Gorlin syndrome, a rare genetic disease characterized by frequent basal cell carcinomas.
Q3 2026 net loss was $12.4 million ($0.58 per share), compared to a net loss of $0.3 million ($0.03 per share) in the same period of 2025, primarily due to a one-time $10 million milestone payment from Torii included in the prior year's results.
Dispensed YCANTH applicator units totaled 19,135 in Q3 2026, representing a 36% year-over-year increase, though a 2.5% sequential decrease was noted attributed to summer travel seasonality.
A conference call to discuss Q3 2026 financial results is scheduled for Thursday, November 12, 2026, at 4:30 pm ET.
Research and development expenses increased to $7.6 million in Q3 2026 from $2.2 million in 2025, driven by non-cash costs related to the common warts Phase 3 program and increased chemistry, manufacturing, and controls expenses.

Company: Verrica Pharmaceuticals
Keywords: Nasdaq:VRCA, Verrica Pharmaceuticals